NASDAQ: HRTX
Heron Therapeutics Inc Stock Ownership - Who owns Heron Therapeutics?

Insider buying vs selling

Have Heron Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Adam MorganDirector2025-08-081,766,546$1.50
$2.65MBuy
Rubric Capital Management LP10% Owner2025-08-082,387,225$1.50
$3.58MBuy

1 of 1

HRTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when HRTX insiders and whales buy or sell their stock.

HRTX Shareholders

What type of owners hold Heron Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Spch LLC25.02%38,174,476$51.54MInsider
Rubric Capital Management LP19.07%29,100,728$39.29MInsider
Rubric Capital Management LP17.51%26,713,503$36.06MInstitution
Perceptive Advisors LLC17.48%26,666,667$36.00MInsider
Blackrock Inc6.62%10,101,715$13.64MInstitution
Adam Morgan5.78%8,823,067$11.91MInsider
Vanguard Group Inc5.55%8,471,460$11.44MInstitution
Adage Capital Partners GP LLC5.15%7,852,000$10.60MInstitution
Velan Capital Investment Management LP4.58%6,986,744$9.43MInstitution
Baker Brothers Life Sciences Capital GP LLC3.45%5,266,568$7.11MInsider

1 of 3

HRTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
HRTX51.53%48.47%Net BuyingNet Buying
ACIU24.40%0.00%
TRDA46.28%53.72%Net SellingNet Selling
IMRX10.54%38.57%Net BuyingNet Buying
SLS25.42%8.22%Net BuyingNet Buying

Heron Therapeutics Stock Ownership FAQ

Who owns Heron Therapeutics?

Heron Therapeutics (NASDAQ: HRTX) is owned by 86.17% institutional shareholders, 81.06% Heron Therapeutics insiders, and 0.00% retail investors. Spch LLC is the largest individual Heron Therapeutics shareholder, owning 38.17M shares representing 25.02% of the company. Spch LLC's Heron Therapeutics shares are currently valued at $51.54M.

If you're new to stock investing, here's how to buy Heron Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.